Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren, K Gao… - Nature …, 2017 - pubmed.ncbi.nlm.nih.gov
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye… - Nature Medicine, 2017 - go.gale.com
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
[CITATION][C] Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye… - Nature Medicine, 2017 - cir.nii.ac.jp
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET
protein stabilization and AKT–mTORC1 activation | CiNii Research CiNii 国立情報学研究所 …
protein stabilization and AKT–mTORC1 activation | CiNii Research CiNii 国立情報学研究所 …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren… - Nature …, 2017 - mayoclinic.elsevierpure.com
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren, K Gao… - Nature …, 2017 - scholars.uthscsa.edu
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
[PDF][PDF] Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye… - Nature …, 2017 - drive.google.com
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye… - Nature …, 2017 - hero.epa.gov
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye… - Nature …, 2017 - europepmc.org
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anti-cancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anti-cancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye… - Nature …, 2017 - europepmc.org
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising
anti-cancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …
anti-cancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor …